Morepen Laboratories liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

6.88×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.37×	2.37×	2.32×	2.21×	2.35×
1.82×	1.82×	1.72×	1.59×	1.64×
171	54.1	105	16.9	21.7
714	673	659	487	435

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MOREPENLAB₹123.55

Morepen Laboratories Limited

· Pharma & Health

₹ CrorePeersIOLCP INNOVACAP FDC ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹6,770 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	6.88
Current Ratio	2.35	2.21	2.32	2.37	2.37
Quick Ratio	1.64	1.59	1.72	1.82	1.82
Cash, Equiv & ST Investments	21.7	16.9	105.2	54.1	171.2
Working Capital	435.0	487.0	658.7	673.3	714.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.